NCT03885141View on ClinicalTrials.gov

Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Insomnia Disorder
Interventions
DRUG

Zolpidem

Zolpidem or Placebo if there is a wake up during the night

Sponsors
All Listed Sponsors
lead

Biolab Sanus Farmaceutica

INDUSTRY